Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 614
- Registration Number
- NCT01153009
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1075
- Registration Number
- NCT01152996
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 506
- Registration Number
- NCT01135368
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
Phase 3
Completed
- Conditions
- GERD
- Interventions
- Drug: Magnesium PantoprazoleDrug: Magnesium Esomeprazole
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 713
- Registration Number
- NCT01132638
- Locations
- 🇧🇷
Investigational site, São Paulo/SP, Brazil
Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Pioglitazone-Azilsartan
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 26
- Registration Number
- NCT01124656
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
Phase 3
Completed
- Conditions
- Prostatic Neoplasms, Locally Advanced
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 273
- Registration Number
- NCT01122121
- Locations
- 🇫🇷
Clinique Mutualiste, Saint-etienne, France
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6198
- Registration Number
- NCT01101035
Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT01084278
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2013-09-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 96
- Registration Number
- NCT01082640
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 314
- Registration Number
- NCT01078389
© Copyright 2025. All Rights Reserved by MedPath